Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis for its CDZ173 to Treat Activated Phosphoinositide 3-kinase Delta Syndrome

Pharming Signs an Exclusive Development and Commercialization Agreement with Novartis for its CDZ173 to Treat Activated Phosphoinositide 3-kinase Delta Syndrome

Shots:

  • Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming will work with Novartis for enrolling patients in ongoing trials  
  • Novartis has accomplished all the preclinical and clinical activities regarding product and will continue to run ongoing registration-enabling trial plus ongoing open label extension study. Post approval of product, Pharming is eligible to commercialize the product in the US and Europe  
  • CDZ173 is a delta isoform of the 110 kDa catalytic subunit of class IA PI3K involved in inhibiting the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3) and is currently evaluated in registration-enabling P-II/III trial. Additionally, it has shown well tolerated & safe results in P-I for APDS patients

Click here to­ read full press release/ article | Ref: Pharming | Image: Industry Hearald24